BTCC / BTCC Square / Global Cryptocurrency /
Kimberly-Clark Downgraded Amid Legal Concerns Over $48.7B Kenvue Acquisition

Kimberly-Clark Downgraded Amid Legal Concerns Over $48.7B Kenvue Acquisition

Published:
2025-11-05 19:55:02
13
3
BTCCSquare news:

Kimberly-Clark's shares fell sharply after Evercore ISI analyst Javier Escalante downgraded the stock from Outperform to In Line, slashing his price target from $150 to $120. The MOVE follows the company's $48.7 billion acquisition of Kenvue, which owns Tylenol—a pain reliever now under scrutiny for potential links to autism.

The U.S. government recently advised pregnant women to avoid Tylenol, amplifying litigation risks. Despite Kimberly-Clark's assertion that the deal creates a $32 billion revenue powerhouse with 10 billion-dollar brands, investors remain wary of the legal overhang.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.